Effects of Recombinant Erythropoietin on Breast Cancer-Initiating Cells

BACKGROUND: Cancer anemia causes fatigue and correlates with poor treatment outcome. Erythropoietin has been introduced in an attempt to correct these defects. However, five recent clinical trials reported a negative impact of erythropoietin on survival and/or tumor control, indicating that experime...

Full description

Bibliographic Details
Main Authors: Tiffany M. Phillips, Kwanghee Kim, Erina Vlashi, William H. McBride, Frank Pajonk
Format: Article
Language:English
Published: Elsevier 2007-12-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558607801229